UK Markets open in 6 hrs 42 mins

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
105.68-1.67 (-1.56%)
At close: 4:00PM EDT
108.40 +2.72 (+2.57%)
After hours: 06:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close107.35
Bid105.68 x 800
Ask108.40 x 900
Day's range105.50 - 107.07
52-week range63.22 - 107.71
Avg. volume1,013,970
Market cap244.369B
Beta (5Y monthly)0.27
PE ratio (TTM)35.79
EPS (TTM)2.95
Earnings dateN/A
Forward dividend & yield1.47 (1.45%)
Ex-dividend date16 Aug 2021
1y target est106.36
  • Motley Fool

    2 Healthcare Stocks You Can Buy and Hold for the Next Decade

    With that in mind, let's turn our attention to two healthcare giants with excellent track records -- Medtronic (NYSE: MDT) and Novo Nordisk (NYSE: NVO) -- and see why both companies may be well worth holding onto for the years ahead. Like many other medical-device specialists, Medtronic had a rough go of it at the peak of the pandemic. Healthcare facilities swamped with COVID-19 patients postponed elective surgeries, leading to lower sales volume for some of Medtronic's products used by physicians.

  • Globe Newswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 25 October 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. Under the programme i

  • Motley Fool

    If I Could Only Own 1 Healthcare Stock, This Is What It Would Be

    It's not that difficult to spread your investments out across many companies and hope for the best over a long time horizon. Another took a different route by making a bet on ARK Genomic Revolution ETF (NYSEMKT: ARKG) in the hope of owning the first healthcare industry trillion-dollar market cap company. Jason Hawthorne (Novo Nordisk): Novo Nordisk is one of three large drug manufacturers that account for the majority of insulin production in the world.